Transforming the way scientists are treating the body’s response to diseases.

The goal of our toll-like receptor (TLR) agonist platform and clinical development program is to tap into the natural function of the immune system from within the tumor environment with our lead TLR9 agonist, IMO-2125, essentially giving the system a boost to affect the treated tumor as well as initiating a reaction from outside the tumor to provide for systemic treatment.

We have demonstrated pre-clinically and more recently clinically, that by combining Ipilimumab (an anti-CTLA4 antibody) , a currently approved treatment for metastatic melanoma, with our intratumoral IMO-2125, we can enable these therapies to have deeper and longer-lasting responses in patients who are refractory to anti-PD1 therapy.

Along with our research alliance partner, MD Anderson Cancer Center, we have recently completed enrollment in the dose escalation phase of our clinical trial of IMO-2125 in combination with Ipilimumab in PD-1 refractory metastatic melanoma patients. Based on all of the evidence generated in the Phase 1 portion of the trial, we’ve selected the 8 mg dosage of IMO-2125 and have advanced to the Phase 2 portion of the trial which will enroll 21 patients at multiple clinical trial sites.  We also are enrolling an arm in the trial to test the combination of IMO-2125 with Pemrolizumab and have recently initiated a multi-center clinical trial of IMO-2125 as a monotherapy in melanoma and numerous other solid tumors and plan to open additional trials to explore further combination regimens in other solid tumor types.  For more information on these studies, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

  • Our Approach

    Learn more about our unwavering dedication to defeating certain cancers and rare diseases.